Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2016

View Archived Issues

Enanta Pharmaceuticals patents FXR agonists

Merck & Co. discloses OX2 receptor antagonists

Sage Therapeutics describes GABA receptor modulators

Eleven Biotherapeutics submits IND for EBI-031, licenses IL-6 technology to Roche

First-in-human data for MGD-010

Wanbang Biopharmaceuticals to prepare IND application for SBM-TFC-039

FDA will review biosimilar application for Amgen's adalimumab

Biosimilar rituximab GP-2013 shows bioequivalence

Clinical trial data delineate activity of pembrolizumab in advanced sarcoma and thyroid cancer

GS-9876: preclinical data

Teva voluntarily suspends sales of Zecuity following adverse application site reactions

Eisai presents latest phase I/II data for E-6011 in rheumatoid arthritis and Crohn's disease

High rate of response seen with SL-401 in blastic plasmacytoid dendritic cell neoplasm

Fibrocell Science starts recruiting patients in study of FCX-007

Revance discontinues development of RT-001 for lateral canthal lines on basis of phase III results

Symic Biomedical reports treatment of first patient with SB-061

Ra Pharmaceuticals discloses phase I results for RA-101495

FDA issues complete response letter for Apadaz

Adamas Pharmaceuticals reports positive results in phase II trial for amantadine

Marinus Pharmaceuticals announces topline results from phase III trial of ganaxolone

Otsuka Pharmaceutical terminates emixustat and OPA-6566 agreements with Acucela

FDA grants fast track designation to ProMetic's IV plasminogen

ContraVir Pharmaceuticals/Ciclofilin Pharmaceuticals merger complete

FDA accepts NDA for CL-108 for review

FDA grants breakthrough therapy designations to Shire's SHP-621 and SHP-625

BioSpecifics Technologies reports positive results on CCH phase II trial

Surface BST2 shows promise as a biomarker for interferon response in patients with SLE

Tyme Technologies begins recruiting for phase Ib/II trial of SM-88

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...